He primarily focuses on the traditional treatment approaches, including lifestyle modifications and pharmacotherapy with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, which have been somewhat effective in slowing the progression of CKD, but have not completely addressed the issue and still are not in universal use in CKD patients, particularly those with increased albuminuria. This evidence concerns the gene ACE and chronic kidney disease.